China takes solid steps to promote higher-quality economic development

China takes solid steps to promote higher-quality economic development

BEIJING, March 6, 2026 /PRNewswire/ -- A report from People's Daily: Chinese President Xi Jinping on March 5 took part in a deliberation with his fellow deputies from the delegation of Jiangsu province at the fourth session of the 14th National...

Locksley Announces High-Grade Antimony Assays at Desert Antimony Mine Confirm Surface Continuity

Locksley Announces High-Grade Antimony Assays at Desert Antimony Mine Confirm Surface Continuity

SAN BERNARDINO, Calif., March 3, 2026 /PRNewswire/ -- Locksley Resources Limited (ASX: LKY; OTCQX: LKYRF/ADR: LKYLY announced high-grade antimony (Sb) assays received from surface exposure grab sampling, with a peak value of 16.90% Sb confirm...

Closing of Flow-Through Private Placement and Public Offering of Common Shares for Gross Proceeds of Approximately C$138 Million

Closing of Flow-Through Private Placement and Public Offering of Common Shares for Gross Proceeds of Approximately C$138 Million

/NOT FOR RELEASE TO U.S. NEWS WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES/ MONTREAL, Feb. 20, 2026 /PRNewswire/ -- February 20, 2026 – Sydney, Australia Highlights Successful closing of the previously announced financings, strengthening...

CGTN: Private economy: A key actor in advancing China's economic priorities in 2026 and beyond

CGTN: Private economy: A key actor in advancing China's economic priorities in 2026 and beyond

BEIJING, Feb. 18, 2026 /PRNewswire/ -- CGTN published an article exploring the Chinese private sector's pivotal role in advancing the priorities of the country's current economic work. The article highlights the significant achievements of private...

Catwalk Entertainment Group signs HK director for Pan-Asian push, propels C-pop to global NBA stage

Catwalk Entertainment Group signs HK director for Pan-Asian push, propels C-pop to global NBA stage

TAIPEI, Feb. 13, 2026 /PRNewswire/ -- Catwalk Entertainment Group, the premier Pan-Asian entertainment conglomerate, today announced a strategic partnership with acclaimed Hong Kong director and screenwriter Tze Yiu Chui. The alliance marks a major...

A 45-year bond: tesa drives innovation and sustainable growth in Singapore

A 45-year bond: tesa drives innovation and sustainable growth in Singapore

Collaboration with impact – Turning partnerships into regional innovation for Singapore's next phase of growth Innovating for tomorrow – Developing next-gen adhesive solutions that meet future industry needs Building sustainable progress – Advancing...

Top 10 News Stories on 2025 Lancang-Mekong Cooperation Released in Luang Prabang

Top 10 News Stories on 2025 Lancang-Mekong Cooperation Released in Luang Prabang

LUANG PRABANG, Laos, Feb. 5, 2026 /PRNewswire/ -- A report by China Report ASEAN: The list of Top 10 News Stories on 2025 Lancang-Mekong Cooperation was officially released on the evening of February 4 (Beijing time) in Luang Prabang, Laos,...

Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem

Nona Biosciences Co-founds Innovative Alliance for Translational Medicine in Immunological Diseases, Advancing a New IIT-Driven Ecosystem

CAMBRIDGE, Mass., Jan. 29, 2026 /PRNewswire/ -- Recently, as a core co-founder and co-organizer, Nona Biosciences participated in the launch of the "Innovative Alliance for Translational Medicine in Immunological Diseases" (the "Alliance") and...

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases...

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans. - ASC37's average in vitro activity was...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 22
  • menu
    menu